Actively Recruiting
Evaluating AAVAnc80-antiVEGF Gene Therapy Using the Akouos Delivery Device for Unilateral Vestibular Schwannoma Treatment
Led by Eli Lilly and Company · Updated on 2026-11-04
27
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of a single unilateral dose of AAVAnc80-antiVEGF gene therapy in adults with unilateral vestibular schwannoma, a condition involving a tumor on the nerve responsible for balance and hearing. This Phase 12 trial also assesses the performance of the Akouos delivery device used to administer the gene therapy. The study aims to understand how well the treatment and device work together to safely deliver the intended therapy. Adult participants receive one of three dose levels of AAVAnc80-antiVEGF through a single intracochlear injection in the affected ear using a sterile, one-time use investigational device called the Akouos Delivery Device. Each participant is assigned to one of three groups, each corresponding to a different dose level. This treatment is given only once per participant in the study ear. During the trial, participants are monitored for adverse events and tumor volume changes for approximately one year after dosing. The study also evaluates the functionality and safety of the delivery device throughout this period. Participants must be willing to comply with all study requirements, including taking part in a separate long-term follow-up after this trial is completed.
CONDITIONS
Brief Title
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Research Team
L
Lilly Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here